flortaucipir
Trade name: Tauvid
Small moleculeapprovedImaging agent
Approved
May 28, 2020
Clinical trial activity
56 trials · 34 clinical orgs · 2 marketing orgs
Phase 1
21
Phase 2
22
Phase 3
5
Phase 4
5
Earliest trial started Apr 1, 2008 (NCT00950430)
Timeline
2010s
- Jan 1, 2012
Avid Radiopharmaceuticals — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2013
Avid Radiopharmaceuticals — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2015
Avid Radiopharmaceuticals — Earliest Phase 3 Sponsor(trial)
2020s
- May 28, 2020
Eli Lilly — Earliest FDA Approval
- May 28, 2020
Avid Radiopharmaceuticals — Marketing Organization
- May 28, 2020
Eli Lilly — NDA Secondary Org
- May 28, 2020
Eli Lilly — NDA Organization
Indications
Studied for
- Alzheimer Disease · Phase 4
- Amyotrophic Lateral Sclerosis · Phase 2
- Atrophy · Phase 2
- Brain Concussion · Phase 1
- Brain Injuries, Traumatic · Phase 2
- Chronic Traumatic Encephalopathy · Phase 2
- Cognition Disorders · Phase 1
- Cognitive Dysfunction · Phase 2
- Corticobasal Degeneration · Phase 1
- Dementia · Phase 2
- Dementia, Vascular · Phase 4
- Depression · Phase 2
- Frontal Lobe · Phase 2
- Frontotemporal Dementia · Phase 4
- HIV · Phase 2
- Lewy Body Disease · Phase 4
- Malformations of Cortical Development · Phase 2
- Neurodegenerative Diseases · Phase 2/Phase 3
- Neuroimaging · Phase 4
- Parkinson Disease · Phase 1
- Pick Disease of the Brain · Phase 1
- Supranuclear Palsy, Progressive · Phase 1
- Tauopathies · Phase 2
- Traumatology · Phase 1
- Whole Body Imaging · Phase 4
Mechanism of action
- Microtubule-associated protein tauBINDING AGENT
MAPT binding agent
- Unspecified targetOTHER
Diagnostic agent
Diagnostic imaging. FLORTAUCIPIR F-18 binds tau aggregates that form in Alzheimer's disease.
Can bind MAO-A and MAO-B in vitro.
Approval history
- approvedPriority reviewMay 28, 2020
Chemistry & pharmacology
Loading structure…
SMILES
[18F]c1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1- Mol. weight
- 262.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL3545253 ↗
- ChEMBLCHEMBL3546271 ↗
Also known as
- (18)av-1451
- (18f)1451
- 18f av 1451
- 18f av 1451
- 18f-av-1451
- 18f-av-1451
- 18f t807
- (18f)t807 compound
- 7-(6-fluoropyridin-3-yl)-5h-pyrido(4,3-b)indole
- av1451
- av-1451
- av-1451
- av-1451
- (f-18)-av-1451
- f-18-av-1451
- t807
- t807
- t-807
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06723015 | Phase 2 | Dec 31, 2024 | Mayo Clinic |
| NCT06297590 | Phase 1 | Aug 15, 2024 | Eli Lilly |
| NCT05361382 | Phase 1 | Nov 23, 2021 | National Institute on Aging (NIA), University of Pittsburgh |
| NCT04926259 | Early Phase 1 (Phase 1) | Nov 1, 2021 | Fujian Medical University |
| NCT03809351 | Phase 1 | Jul 8, 2020 | University of Alabama, Birmingham |
| NCT04417998 | Phase 4 | Jun 1, 2020 | Mayo Clinic |
| NCT04263337 | Phase 1 | Mar 12, 2020 | Harvard University, Medical College of Wisconsin, University of North Carolina at Chapel Hill |
| NCT04080544 | Phase 2 | Sep 15, 2019 | The University of Texas, Dallas |
| NCT03816228 | Phase 2 | Jul 31, 2019 | Washington University in St. Louis |
| NCT03718494 | Phase 4 | Jun 30, 2019 | Columbia University, Harvard University, Mayo Clinic, National Institute on Aging (NIA), University of Arizona, University of California, San Francisco, Utah State University, Yale University |
| NCT03821857 | Phase 4 | Jun 27, 2019 | Mayo Clinic, National Institute on Aging (NIA) |
| NCT03901105 | Phase 3 | Mar 28, 2019 | Avid Radiopharmaceuticals |
| NCT03901092 | Phase 3 | Mar 26, 2019 | Avid Radiopharmaceuticals |
| NCT03582488 | Phase 4 | Jun 25, 2018 | Mayo Clinic |
| NCT03467477 | Phase 2 | Mar 8, 2018 | Avid Radiopharmaceuticals |
| NCT03322462 | Phase 2 | Oct 26, 2017 | Avid Radiopharmaceuticals |
| NCT03189485 | Early Phase 1 (Phase 1) | Aug 31, 2017 | National Institute on Aging (NIA), National Institutes of Health (NIH), University of Pennsylvania |
| NCT03040713 | Phase 1 | Apr 11, 2017 | Avid Radiopharmaceuticals |
| NCT03052972 | Phase 1 | Mar 23, 2017 | Avid Radiopharmaceuticals |
| NCT03022968 | Phase 2 | Jan 10, 2017 | University of Toulouse |
Showing 20 of 56 trials
Page 1 / 3
Organizations
Research & Development (34)
34 organizations
Page 1 / 2
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Avid Radiopharmaceuticals | For profit | MKTG | May 28, 2020 |
| Eli Lilly | For profit | NDA2 | May 28, 2020 |
| Eli Lilly | For profit | NDA | May 28, 2020 |